New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2013
05:55 EDTARTC, ARTC, ARTC, ARTC, ARTC, MDT, MDT, MDT, MDT, MDT, MGLN, MGLN, MGLN, MGLN, MGLN, MAKO, MAKO, MAKO, MAKO, MAKO, KYO, KYO, KYO, KYO, KYO, ECL, ECL, ECL, ECL, ECL, COV, COV, COV, COV, COV, CYH, CYH, CYH, CYH, CYH, CFN, CFN, CFN, CFN, CFN, BMTI, BMTI, BMTI, BMTI, BMTI, BAX, BAX, BAX, BAX, BAX, AXGN, AXGN, AXGN, AXGN, AXGN, AUXL, AUXL, AUXL, AUXL, AUXL, OSIR, OSIR, OSIR, OSIR, OSIRAmerican Academy of Orthopaedic Surgeons to host annual meeting
AAOS 2013 Annual Meeting is being held in Chicago on March 19-23.
News For ARTC;AUXL;AXGN;BAX;BMTI;CFN;CYH;COV;ECL;KYO;MAKO;MGLN;MDT;OSIR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 18, 2014
06:41 EDTCYHCommunity Health initiated with a Buy at Sterne Agee
Subscribe for More Information
December 17, 2014
10:51 EDTCYH, MGLNLeerink healthcare services analyst holds analyst/industry conference call
Healthcare Services Analyst Gupte provides outlook and favorite names for 2015 in the Hospitals and Managed Care Industry on an Analyst/Industry conference call to be held on December 18 at 1 pm.
05:48 EDTCFNBecton Dickinson named 2015 large cap top pick at Piper Jaffray
Piper Jaffray raised its price target for Becton Dickinson (BDX) shares to $160 from $141 and called the stock its 2015 large cap top pick. Piper expects upside to management's CareFusion (CFN) merger earnings accretion guidance and sees potential gross margin benefit from falling oil prices. The firm keeps an Overweight rating on the stock. Shares of the medical technology company closed yesterday down $1.71 to $134.04.
December 16, 2014
16:53 EDTAUXLAuxilium updates court findings in Actavis testosterone gel patent suit
Auxilium (AUXL) disclosed in a filing that as previously disclosed, on May 23 , Auxilium Pharmaceuticals, and FCB I LLC, as licensor of Testim, filed a lawsuit in the U.S. District Court for the District of New Jersey against Actavis (ACT) for infringement of FCB’s 10 patents listed in the Orange Book as covering Testim testosterone gel. The lawsuit was filed in response to a notice letter, dated April 12, 2012, sent by Actavis Laboratories, regarding its filing with the U.S. Food and Drug Administration of an Abbreviated New Drug Application for a generic 1% testosterone gel product. This letter also stated that the ANDA contained Paragraph IV certifications with respect to the nine patents listed in the Orange Book on that date as covering Testim. The company’s lawsuit filed against Actavis initially involved those nine patents, as well as a 10th patent covering Testim that was issued on May 15, 2012 and is listed in the Orange Book. By the time that the trial commenced in September 2014, the parties had agreed to remove all but one of those patents from the litigation, with the trial focused solely on claim 3 of U.S. Patent # 7,608,607 . The trial commenced in September 2014 and closing arguments occurred in November 2014. On December 16 , the company learned that Judge Linares held that claim 3 of the ‘607 patent is invalid for obviousness. The Judge also found claim 3 invalid for derivation and improper inventorship, but he declined to rule on whether correction of inventorship would be appropriate because it would be futile in light of his ruling on obviousness. Auxilium believes that Actavis is now free to enter the market with its testosterone gel product once it obtains approval from the FDA. At this time, Auxilium is not aware of Actavis having received tentative approval or final approval from the FDA for its testosterone gel product. Auxilium is analyzing the District Court’s opinion and will explore its available options with regard to this matter.
15:01 EDTCYHJudge says Obama's immigration orders unconstitutional, Politico says
Subscribe for More Information
08:58 EDTAUXLEndo a top pick for 2015, says Sterne Agee
Subscribe for More Information
06:36 EDTMGLNMagellan Health reaffirms FY14 guidance
The company confirmed its FY14 guidance, which was most recently updated in October. “We’ve made great progress this year on our plan for growth, primarily related to our Magellan Complete Care and Pharmacy Management initiatives,” said the company. “In MCC, we are managing the total care of individuals with complex needs. We serve those with serious mental illness in Florida, and Medicaid Managed Long Term Care recipients in New York. In our pharmacy business, we now offer full service pharmacy capabilities to manage the entire drug spend of populations for health plan, employer, and government customers. We will continue to solidify our leadership position in population health management in the coming years across our behavioral health, pharmacy and specialty solutions businesses.”
06:34 EDTMGLNMagellan Health sees FY 15 adj. EPS $3.28-$3.73, consensus $2.67
Sees FY15 revenue $4.25B-$4.49B, consensus $4.47B. Sees FY15 EPS $1.90-$2.50, inclusive of share repurchases to date. For 2015, the company is assuming weighted average shares outstanding of 26.8M. The company also expects segment profit to be in the range of $265M-$285M. Cash flow from operations is expected to be in the range of $171M-$195M.
December 15, 2014
09:03 EDTBAXBaxter to divest Vero cell vaccines platform to Nanotherapeutics
Baxter International (BAX) announced that it has entered into a definitive agreement to sell its proprietary Vero cell technology and related assets, including its production facility in Bohumil, Czech Republic, to Nanotherapeutics, Inc. Financial details were not disclosed. The agreement with Nanotherapeutics includes all assets related to the platform, including vaccines for H5N1, H1N1 and seasonal influenza. The agreement also includes investigational vaccine programs for Ross River virus, Chikungunya disease and West Nile virus. In recent weeks, the company has also completed the sale of its commercial vaccines business and related manufacturing facilities to Pfizer (PFE).
December 12, 2014
13:52 EDTCYHLeerink healthcare services analyst holds an analyst/industry conference call
Subscribe for More Information
December 11, 2014
17:04 EDTAUXLEndo registration statement relating to Auxilium declared effective by SEC
Subscribe for More Information
09:40 EDTAXGNAxoGen management to meet with Lake Street
Meetings to be held in Minneapolis on December 17 and in San Francisco on December 18 hosted by Lake Street.
09:05 EDTMDTMedtronic receives FDA approval for Attain Performa LV quadripolar leads
Subscribe for More Information
08:00 EDTCYHCommunity Health to divest Newport, Arkansas hospital
Community Health Systems announced that subsidiaries of the company have executed a definitive agreement to sell substantially all of the assets of 133-bed Harris Hospital in Newport, Arkansas, along with related outpatient services, to White County Medical Center of Searcy, Arkansas. The divestiture is expected to close early in the first quarter of 2015, subject to customary regulatory approvals and closing conditions. The company does not expect the divestiture to have a meaningful impact on financial operations. Following the divestiture of Harris Hospital, Community Health Systems affiliates will continue to operate nine hospitals in Arkansas.
December 10, 2014
17:19 EDTBAXBaxter announces filing of Form 10 in connection with planned spin-off
Subscribe for More Information
14:16 EDTMGLNMagellan Health to host conference call
Subscribe for More Information
December 9, 2014
12:22 EDTBAXPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
December 8, 2014
08:31 EDTCFNBecton Dickinson and CareFusion sets date for special meeting in proposed merger
Becton, Dickinson (BDX) and CareFusion (CFN) announced that CareFusion expects to hold a special meeting on January 21, 2015 for CareFusion stockholders to consider and vote upon the proposed merger of CareFusion and BD. As previously announced on October 5, 2014, BD and CareFusion entered into a definitive agreement pursuant to which BD would acquire CareFusion in a stock and cash transaction. CareFusion stockholder approval is a condition to the merger. In addition to CareFusion stockholder approval, the proposed acquisition remains subject to certain other conditions and approvals, including approval of the proposed acquisition by the European Commission under the European Union Merger Regulation. CareFusion has fixed the close of business on December 18, 2014 as the record date for the purpose of determining the stockholders who are entitled to notice of, and to vote at, the special meeting.
08:22 EDTCYHCommunity Health management to meet with Deutsche Bank
Subscribe for More Information
08:13 EDTCFNCareFusion announces agreement with Medacist
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use